Topic Review
Artificial Intelligence for Academic Advanced Therapy Medicinal Products
Advanced therapy medicinal products (ATMPs), encompassing cell and gene therapies, hold immense promise in revolutionizing treatment options for numerous diseases. However, the translation of these innovative therapies from research to clinical practice faces formidable challenges, necessitating the establishment of specialized manufacturing facilities within hospital settings. Hospital-based Good Manufacturing Practice (GMP) facilities offer a unique advantage by enabling rapid bench-to-bedside development and direct patient access, yet their implementation necessitates significant adaptation within healthcare infrastructures, constrained by spatial limitations, regulatory requirements, and resource allocation. Key considerations and solutions for overcoming these challenges are paramount for realizing the full potential of ATMPs. Proximity afforded by on-site manufacturing facilitates direct delivery to patients, mitigating risks associated with transportation and ensuring timely access to cutting-edge therapies. Moreover, aligning production schedules with clinical demands enhances flexibility and responsiveness to patient needs. However, the integration of pharmaceutical manufacturing within hospital environments necessitates addressing critical gaps in staff training, documentation practices, and oversight, which are inherent to the highly regulated pharmaceutical industry. Significant investments in infrastructure, specialized equipment, personnel training, and multi-departmental coordination are indispensable for establishing and maintaining robust hospital ATMP facilities. Embracing technological advancements, such as process analytical technology (PAT), continuous manufacturing, and artificial intelligence (AI), holds immense potential in bolstering the efficiency, quality, and safety of ATMP production processes. AI, in particular, offers the capability to analyze vast datasets generated during manufacturing, facilitating real-time prediction of product quality attributes and enabling automated adjustments through feedback control mechanisms. Despite these technological advancements, challenges persist in integrating AI into pharmaceutical manufacturing due to concerns regarding data security, regulatory compliance, and the requisite multidisciplinary collaboration. Successful adoption of AI technologies necessitates simultaneous investment in human capital to ensure effective implementation and governance. Ultimately, the convergence of innovative manufacturing technologies and synergistic partnerships across disciplines is paramount for realizing the transformative potential of ATMPs, ensuring their responsible translation from research to clinical impact while maximizing therapeutic safety and efficacy.
  • 125
  • 23 Feb 2024
Topic Review
Selective Vulnerability to Neurodegenerative Disease
Neurodegenerative diseases (NDs) manifest a wide variety of clinical symptoms depending on the affected brain regions. Gaining insights into why certain regions are resistant while others are susceptible is vital for advancing therapeutic strategies. While gene expression changes offer clues about disease responses across brain regions, the mixture of cell types therein obscures experimental results. 
  • 135
  • 23 Feb 2024
Topic Review
Inflammatory Biomarkers and Gait Impairment in Older Adults
Peripheral inflammation and gait speed alterations are common in several neurological disorders and in the aging process, but the association between the two is not well established. Biomarkers play an important role in the decision-making process, and IL-6 can be an effective biomarker in establishing the diagnosis of slow gait speed. Further longitudinal research is needed to establish the use of molecular biomarkers in monitoring gait impairment.
  • 217
  • 23 Feb 2024
Topic Review
Mycorrhiza in Pines
Mycorrhiza is one of the fundamental phenomena of nature, characteristic of land plants from the moment of their formation, representing a form of symbiosis between plants, fungi, and bacteria.
  • 255
  • 22 Feb 2024
Topic Review
Reciprocal Effects of Metal Mixtures on Phytoplankton
Phytoplankton are a key part of marine and freshwater ecosystems as primary producers of the food web. They are exceptional in their role in heavy metals bioremediation. Algae and cyanobacteria when exposed to metals in mixture, show altered responses as compared to the single metal exposure. Algal parameters such as growth, chlorophyll content, photosynthesis, metal uptake and metabolism, or lipid profile are commonly determined to find out the level of stress in algal cells resulting from heavy metals. Phytoplankton have several pathways of metal entry, detoxification and tolerance. It is essential to estimate reciprocal toxicity of metals as in real-time, metals are released in the environment in bulk (reciprocal effects). Phytoplankton can be a powerful tool in such risk assessments. 
  • 129
  • 22 Feb 2024
Topic Review
Incidence of Otolaryngological Manifestations in Individuals with ASD
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impairments with social interaction as well as restricted and stereotyped behaviors. Other hallmarks of ASD include a delay in speech and language development, delay in developmental milestones, and eye contact avoidance.
  • 147
  • 22 Feb 2024
Topic Review
Wound Repair of the Cell Membrane
The cell membrane is frequently subjected to damage, either through physical or chemical means. The swift restoration of the cell membrane’s integrity is crucial to prevent the leakage of intracellular materials and the uncontrolled influx of extracellular ions. Consequently, wound repair plays a vital role in cell survival, akin to the importance of DNA repair.
  • 88
  • 22 Feb 2024
Topic Review
Application of Microbial Cell Factories
Microbial cell factories are becoming a fundamental technology for pharmaceutical, food, and chemical industries to satisfy the welfare of an increasing global population and socio-economic development. Microorganisms are used for the production of various products, including carboxylic acids, amino acids, vitamins, enzymes, plant natural products, carotenoids, biogas, and other biofuels. About 52% of FDA-approved chemical entities were naturally derived products during the period of 1981–2006. The production of varied value-added macromolecules and metabolites was witnessed in the last decade by microbial cell factories (MCFs), with titers changing from μg/L to mg/L. Moreover, the introduction of metabolic engineering approaches improved the rate, titer, and yield of industrially vital compounds by manipulating the host metabolism, physiology, stress response, carbon–energy balance, and the annihilation of an undesirable ATP sink. Due to MCFs, the industrial biotechnology sector is increasing expeditiously, and numerous biocommodities are also in production. 
  • 132
  • 22 Feb 2024
Topic Review
HIV Vaccine Development Based on Tat
Vaccination is undoubtedly the most cost-effective intervention to curb the HIV pandemic, both in the preventative and therapeutic setting. Based on the epidemiological evidence and experimental data indicating a protective role for anti-Tat immunity, in particular of anti-Tat Abs, the development of vaccines based on Tat was undertaken.
  • 81
  • 22 Feb 2024
Topic Review
Viper Venom Phospholipase A2
Viper venom phospholipase A2 enzymes (vvPLA2s) and phospholipase A2-like (PLA2-like) proteins are two of the principal toxins in viper venom that are responsible for the severe myotoxic and neurotoxic effects caused by snakebite envenoming, among other pathologies. 
  • 146
  • 22 Feb 2024
  • Page
  • of
  • 1746
Video Production Service